IOMED®, Inc. (AMEX:IOX) develops, manufactures, and markets controllable drug delivery systems using iontophoretic technology. Iontophoresis is a non-invasive, needle-free method of enhancing and controlling the transport of water-soluble ionic (electrically charged) drugs into and through the skin using a low level electrical current. IOMED went public in 1998.